Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction.
about
Inherited platelet disorders: toward DNA-based diagnosisThe emerging role of oxylipins in thrombosis and diabetesHigh-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literaturePhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionPlatelet lipidomics: modern day perspective on lipid discovery and characterization in plateletsAdvances in Our Understanding of Oxylipins Derived from Dietary PUFAsFunctional characterization of mutations in inherited human cPLA₂ deficiencyPhospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizationsA Hereditary Enteropathy Caused by Mutations in the SLCO2A1 Gene, Encoding a Prostaglandin TransporterTranscription Factor RUNX1 Regulates Platelet PCTP (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events.cPLA2 is protective against COX inhibitor-induced intestinal damage.Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation.Analysis of candidate colitis genes in the Gdac1 locus of mice deficient in glutathione peroxidase-1 and -2.Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2α differently for cyclooxygenase-1 and 12-lipoxygenase catalysis.Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology.Cytosolic phospholipase A₂: physiological function and role in disease.Cytosolic phospholipase A2 contributes to innate immune defense against Candida albicans lung infectionSuboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation.Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.Group IVA cytosolic phospholipase A2 (cPLA2alpha) and integrin alphaIIbbeta3 reinforce each other's functions during alphaIIbbeta3 signaling in plateletsThe involvement of phospholipases A2 in asthma and chronic obstructive pulmonary diseasePhospholipase A2 structure/function, mechanism, and signaling.Golgi-associated cPLA2alpha regulates endothelial cell-cell junction integrity by controlling the trafficking of transmembrane junction proteins.A PLA1-2 punch regulates the Golgi complex.Cytosolic phospholipase A2α promotes pulmonary inflammation and systemic disease during Streptococcus pneumoniae infection.New Concepts and Mechanisms of Platelet Activation Signaling.Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma MetastasisLipolysis meets inflammation: arachidonic acid mobilization from fat.The enteropathy of prostaglandin deficiency.Lipoquality control by phospholipase A2 enzymes.Kidney Transplantation in a Patient Lacking Cytosolic Phospholipase A2 Proves Renal Origins of Urinary PGI-M and TX-M.Dietary modulation of oxylipins in cardiovascular disease and aging.
P2860
Q26752148-F6D30F67-4B7A-473E-877C-12CF96096479Q26823893-F7394044-452C-448A-A23B-9EE1F3F2D014Q26996600-FCFABC89-E316-4806-96F2-5251E53B0AE5Q26997377-8E80F80F-61DC-4D84-8668-E92A850DE12BQ26998976-DBEE4AF0-72D3-4151-90BE-9503383053D0Q27014988-5E2B828F-418F-4C31-94D4-A4CBFC7AD9E8Q28116071-2D54D9AD-BCF6-4069-8985-76BA35622351Q28286551-963892B1-D8C6-47F6-87F6-49BC1FC617DFQ28550714-5BF0AE14-4F34-41ED-BEDD-3823084D444AQ33443278-4EC4B921-F44F-4D33-86EE-6308CD87A7CDQ34072006-7E2BA587-FC64-4597-AE2F-BD0803E30862Q34154684-209CBBDB-415A-4E4D-BD95-7E686982FE6BQ34412323-52F6FDDA-3367-41FE-BE14-5C8D55B8BB93Q34560219-278A7CE2-66E6-407F-9DFA-BF85CC32D86AQ34952213-26F09BBA-724E-4117-83D6-73B3EEE47316Q35886245-8CA0989A-F793-4A66-A51F-0FCF5F73063DQ36097784-098B55FF-3236-4D01-834B-CC35F5629303Q36163277-91C8D310-038C-4FDA-ABC3-44E2D55C8D88Q36171277-9B873D02-3E9E-44E4-942E-96B0E90EC18CQ36620215-44536D00-BFA5-4A87-B37E-7B1DC444EFDAQ37041937-497DF18E-10F6-4801-9817-40B707CB77D3Q37191456-E6A31382-7260-4E78-9836-40D5D49943ECQ37326136-320FC7E4-D408-4363-9332-9A1A535AE936Q37369889-16488BDB-F5B6-4510-B90F-DCEEDDE562DDQ37963183-32F91E62-9730-4E46-92C3-3A696DC56C60Q38624971-3C874A9B-267A-4962-AAEC-5219B7EDBBEBQ39147112-AE3808AA-9BD0-4593-928E-0CA41465F44CQ42731074-9CA0D6F9-59B8-49D1-B4D0-F405F38F060CQ42797255-0206E013-6E9C-4C02-98E8-A5D66F732842Q42945875-FFA5DC6F-0D51-4954-B6E8-71836FBF2DBCQ47133692-3C683359-8AFE-4654-9A02-E2866224B1B3Q47213061-AED7C7EF-42A7-4994-8810-3E2C71B8394CQ48157381-D6CE0AAB-B180-4BC3-AD9C-12EB170FDE42
P2860
Inherited human cPLA(2alpha) deficiency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@ast
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@en
type
label
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@ast
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@en
prefLabel
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@ast
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@en
P2093
P2860
P356
P1476
Inherited human cPLA(2alpha) d ...... ion, and platelet dysfunction.
@en
P2093
David H Adler
Jason D Morrow
Jeffrey A Stein
John A Oates
John A Phillips
Joy D Cogan
Nathalie Schnetz-Boutaud
Olivier Boutaud
Tina Iverson
P2860
P304
P356
10.1172/JCI30473
P407
P577
2008-06-01T00:00:00Z